These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 14747554)

  • 1. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
    Feng WH; Hong G; Delecluse HJ; Kenney SC
    J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
    Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
    Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.
    Lee HG; Kim H; Kim EJ; Park PG; Dong SM; Choi TH; Kim H; Chong CR; Liu JO; Chen J; Ambinder RF; Hayward SD; Park JH; Lee JM
    Oncotarget; 2015 Oct; 6(31):31018-29. PubMed ID: 26427042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.
    Daibata M; Bandobashi K; Kuroda M; Imai S; Miyoshi I; Taguchi H
    J Virol; 2005 May; 79(9):5875-9. PubMed ID: 15827204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cordycepin enhances Epstein-Barr virus lytic infection and Epstein-Barr virus-positive tumor treatment efficacy by doxorubicin.
    Du Y; Yu J; Du L; Tang J; Feng WH
    Cancer Lett; 2016 Jul; 376(2):240-8. PubMed ID: 27063964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
    Novalić Z; Verkuijlen SAWM; Verlaan M; Eersels JLH; de Greeuw I; Molthoff CFM; Middeldorp JM; Greijer AE
    J Med Virol; 2017 Dec; 89(12):2207-2216. PubMed ID: 28853217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
    Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
    Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
    Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
    Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
    Hsu CL; Kuo YC; Huang Y; Huang YC; Lui KW; Chang KP; Lin TL; Fan HC; Lin AC; Hsieh CH; Lee LY; Wang HM; Li HP; Chang YS
    Oncotarget; 2015 Oct; 6(31):31323-34. PubMed ID: 26416517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.
    Feng WH; Israel B; Raab-Traub N; Busson P; Kenney SC
    Cancer Res; 2002 Mar; 62(6):1920-6. PubMed ID: 11912175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new compound, phomaherbarine A, induces cytolytic reactivation in epstein-barr virus-positive B cell lines.
    Bae SE; Choi JW; Hong JW; Ku H; Sim KY; Ko GH; Jang DS; Shim SH; Park SG
    Antiviral Res; 2024 Jul; 227():105906. PubMed ID: 38735576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
    Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
    J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-10 knockdown with siRNA enhances the efficacy of Doxorubicin chemotherapy in EBV-positive tumors by inducing lytic cycle via PI3K/p38 MAPK/NF-kB pathway.
    Gao L; Han H; Wang H; Cao L; Feng WH
    Cancer Lett; 2019 Oct; 462():12-22. PubMed ID: 31352079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
    Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
    PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
    Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
    mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
    Robinson AR; Kwek SS; Kenney SC
    PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ; Perrine SP; Faller DV
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
    Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
    Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.